Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C17H25NO4.ClH |
| Molecular Weight | 343.846 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.COC1=CC(OC)=C(C(=O)CCCN2CCCC2)C(OC)=C1
InChI
InChIKey=ZDPACSAHMZADFZ-UHFFFAOYSA-N
InChI=1S/C17H25NO4.ClH/c1-20-13-11-15(21-2)17(16(12-13)22-3)14(19)7-6-10-18-8-4-5-9-18;/h11-12H,4-10H2,1-3H3;1H
| Molecular Formula | C17H25NO4 |
| Molecular Weight | 307.3847 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | ClH |
| Molecular Weight | 36.461 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
DescriptionCurator's Comment: description was created based on several sources, including
https://www.drugs.com/international/buflomedil.html | https://www.ncbi.nlm.nih.gov/pubmed/3784966 | https://www.ncbi.nlm.nih.gov/pubmed/26193704 | http://www.medscape.com/viewarticle/753768
Curator's Comment: description was created based on several sources, including
https://www.drugs.com/international/buflomedil.html | https://www.ncbi.nlm.nih.gov/pubmed/3784966 | https://www.ncbi.nlm.nih.gov/pubmed/26193704 | http://www.medscape.com/viewarticle/753768
Buflomedil (trade name Loftyl) is a vasoactive drug used to treat claudication or the symptoms of peripheral arterial disease. Buflomedil has been used for people with diseases of the leg arteries and has shown some benefits for people with a previous stroke. The most common type of stroke is due to narrowing or blockage of an artery in the brain (i.e. ischaemic stroke). Buflomedil is a drug that can dilate brain blood vessels, which may have benefit for people with ischaemic stroke. However, it has not been approved to treat stroke in clinical practice. In 2012 the European Medicines Agency has completed a review of the safety and effectiveness of buflomedil-containing medicines, both oral and injectable, due to severe neurological and cardiac side effects seen with buflomedil. The Agency’s Committee for Medicinal Products for Human Use (CHMP) concluded that the benefits of buflomedil do not outweigh its risks, and has recommended that all marketing authorisations for medicines containing buflomedil should be suspended throughout the European Union (EU).
Originator
Approval Year
AUC
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
2.32 mg × h/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7286057/ |
50 mg single, intravenous dose: 50 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
BUFLOMEDIL serum | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
4.52 mg × h/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7286057/ |
100 mg single, intravenous dose: 100 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
BUFLOMEDIL serum | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
9.26 mg × h/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7286057/ |
200 mg single, intravenous dose: 200 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
BUFLOMEDIL serum | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
T1/2
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
3.29 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7286057/ |
50 mg single, intravenous dose: 50 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
BUFLOMEDIL serum | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
3.07 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7286057/ |
100 mg single, intravenous dose: 100 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
BUFLOMEDIL serum | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
3.39 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7286057/ |
200 mg single, intravenous dose: 200 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
BUFLOMEDIL serum | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Profiling of a prescription drug library for potential renal drug-drug interactions mediated by the organic cation transporter 2. | 2011-07-14 |
|
| Influence of pharmacological treatment on blood flow and muscle perfusion in patients with obliterative atheromatosis assessed with isotopic methods. A pilot study. | 2010-12 |
|
| [Addition of antithrombosis in situ in the case of digital replantation: preliminary prospective study of 13 cases]. | 2010-10 |
|
| Silence of the limbs pharmacological symptomatic treatment of intermittent claudication. | 2010-05 |
|
| [Multicentric study of thrombosis prevention in upper-extremity microsurgery. Survey at the Fesum centers]. | 2010-04 |
|
| Surgical management of a diabetic calcaneal ulceration and osteomyelitis with a partial calcanectomy and a sural neurofasciocutaneous flap. | 2010 |
|
| Buflomedil: potential new indications for an old agent. | 2009-06 |
|
| Pharmacologic therapy for intermittent claudication. | 2009-05 |
|
| Endothelin and sex hormones modulate the fibronectin synthesis by cultured human skin scleroderma fibroblasts. | 2009-04 |
|
| [Severe peripheral ischemia of rare origin]. | 2009-03-19 |
|
| Naftidrofuryl for intermittent claudication: meta-analysis based on individual patient data. | 2009-03-10 |
|
| Cutaneous granulomatous reaction from mesotherapy. | 2009-02 |
|
| Effects of buflomedil and pentoxifylline on hamster skin-flap microcirculation: prediction of flap viability using orthogonal polarization spectral imaging. | 2009 |
|
| Bias in benefit-risk appraisal in older products: the case of buflomedil for intermittent claudication. | 2009 |
|
| Letter by De Backer et al regarding article, "Oral buflomedil in the prevention of cardiovascular events in patients with peripheral arterial obstructive disease: a randomized, placebo-controlled, 4-year study". | 2008-09-02 |
|
| Oral vasodilators for primary Raynaud's phenomenon. | 2008-04-16 |
|
| Effectiveness of mesotherapy on body contouring. | 2008-04 |
|
| Simultaneous FTIR spectroscopic imaging and visible photography to monitor tablet dissolution and drug release. | 2008-04 |
|
| The use of buflomedil in reduction mammaplasty for a previously irradiated breast: a case report. | 2008-03 |
|
| Buflomedil in peripheral arterial disease: trials and tribulations. | 2008-02-12 |
|
| Oral buflomedil in the prevention of cardiovascular events in patients with peripheral arterial obstructive disease: a randomized, placebo-controlled, 4-year study. | 2008-02-12 |
|
| Buflomedil for intermittent claudication. | 2008-01-23 |
|
| Long-term follow-up of hypothenar hammer syndrome: a series of 47 patients. | 2007-11 |
|
| Buflomedil for intermittent claudication. | 2007-10-17 |
|
| Sensitive and rapid LC-ESI-MS method for the determination of trimetazidine in human plasma. | 2007-06-28 |
|
| [Adenosine for treatment of ischemic pain in thromboangiitis obliterans. A case report]. | 2007-06 |
|
| Buflomedil: still seizures and cardiac disorders. Too many patients are exposed to an unjustified risk of serious adverse effects. | 2007-02 |
|
| Preclinical and clinical examinations of Salvia miltiorrhiza and its tanshinones in ischemic conditions. | 2006-11-23 |
|
| The effects of prostaglandin E-1 in patients with intermittent claudication. | 2006-06 |
|
| Comparison between intravenous iloprost and vasoactive drugs in limb ischemia IIB severe. A retrospective analysis. | 2006-06 |
|
| Assemblage of novel release modules for the development of adaptable drug delivery systems. | 2006-03-10 |
|
| Detailed documentation of one lipolysis treatment: blood values, histology, and ultrasound findings. | 2006-02-19 |
|
| Facilitated column selection in pharmaceutical analyses using a simple column classification system. | 2006-01-06 |
|
| Buflomedil and pentoxifylline in the viability of dorsal cutaneous flaps of rats treated with nicotine. | 2006 |
|
| [Pharmaceutical analysis and validation of hospital prescriptions, a 5-year study]. | 2005-08-27 |
|
| Does Danshen improve disability after acute ischaemic stroke? | 2005-02 |
|
| Effect of loading on a swelling-controlled drug delivery system studied by optical techniques. | 2005-01-03 |
|
| Therapy of hearing disorders - conservative procedures. | 2005 |
|
| Local hyperemia to heating is impaired in secondary Raynaud's phenomenon. | 2005 |
|
| Protective effect of buflomedil in a rat model of moderate cerebral ischemia. | 2005 |
|
| Inhibitory effect of buflomedil on prostate alpha1A adrenoceptor in the Wistar rat. | 2004-09-02 |
|
| Rapid and sensitive liquid chromatography-electrospray ionization-mass spectrometry method for the determination of eperisone in human plasma: method and clinical applications. | 2004-06-11 |
|
| [Secondary prevention and conservative therapy of obliterative arteriosclerosis]. | 2004-05-16 |
|
| [Suicidal buflomedil intoxication]. | 2004-05-13 |
|
| Development of pulsatile release tablets with swelling and rupturable layers. | 2004-03-05 |
|
| Suicide by buflomedil HCl: a case report. | 2004-02 |
|
| Drug treatment of intermittent claudication. | 2004 |
|
| [Sudden hearing loss. Clinical case]. | 2002 |
|
| Ticlopidine-pentoxifylline combination in the treatment of atherosclerosis and the prevention of cerebrovascular accidents. | 1989-01-01 |
|
| [Emetic and catalepsy-inducing actions of buflomedil]. | 1988-12 |
Patents
Sample Use Guides
The effect of buflomedil (Fonzylane; Laboratoire Lafon, Maisons-Alfort, France) on platelet function, a drug used clinically for the treatment of peripheral vascular diseases, was investigated in vitro. The compound significantly inhibits epinephrine-induced aggregation at the micromolar level. At higher doses (approximately 1 mM), a weak inhibition of ADP- and collagen-induced aggregation was observed; at these concentrations, buflomedil inhibits granular secretion and the interaction of fibrinogen with its receptor on platelet. Further investigations indicate that the drug affects calcium uptake at the membrane level and inhibits the binding of [3H]-yohimbine to the same extent as observed with phentolamine. The IC50 determined from competition binding assays was 1 +/- 0.5 microM.
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 18:04:34 GMT 2025
by
admin
on
Mon Mar 31 18:04:34 GMT 2025
|
| Record UNII |
3J944AFS8S
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Brand Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
235934
Created by
admin on Mon Mar 31 18:04:34 GMT 2025 , Edited by admin on Mon Mar 31 18:04:34 GMT 2025
|
PRIMARY | RxNorm | ||
|
3J944AFS8S
Created by
admin on Mon Mar 31 18:04:34 GMT 2025 , Edited by admin on Mon Mar 31 18:04:34 GMT 2025
|
PRIMARY | |||
|
35543-24-9
Created by
admin on Mon Mar 31 18:04:34 GMT 2025 , Edited by admin on Mon Mar 31 18:04:34 GMT 2025
|
PRIMARY | |||
|
DTXSID6046977
Created by
admin on Mon Mar 31 18:04:34 GMT 2025 , Edited by admin on Mon Mar 31 18:04:34 GMT 2025
|
PRIMARY | |||
|
252-611-9
Created by
admin on Mon Mar 31 18:04:34 GMT 2025 , Edited by admin on Mon Mar 31 18:04:34 GMT 2025
|
PRIMARY | |||
|
759291
Created by
admin on Mon Mar 31 18:04:34 GMT 2025 , Edited by admin on Mon Mar 31 18:04:34 GMT 2025
|
PRIMARY | |||
|
100000090428
Created by
admin on Mon Mar 31 18:04:34 GMT 2025 , Edited by admin on Mon Mar 31 18:04:34 GMT 2025
|
PRIMARY | |||
|
m2750
Created by
admin on Mon Mar 31 18:04:34 GMT 2025 , Edited by admin on Mon Mar 31 18:04:34 GMT 2025
|
PRIMARY | Merck Index | ||
|
SUB00891MIG
Created by
admin on Mon Mar 31 18:04:34 GMT 2025 , Edited by admin on Mon Mar 31 18:04:34 GMT 2025
|
PRIMARY | |||
|
37170
Created by
admin on Mon Mar 31 18:04:34 GMT 2025 , Edited by admin on Mon Mar 31 18:04:34 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
PARENT -> SALT/SOLVATE |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
IMPURITY -> PARENT |
|
||
|
IMPURITY -> PARENT |
|
||
|
IMPURITY -> PARENT |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |